Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies.
10.3881/j.issn.1000-503X.11534
- Author:
Hui TANG
1
;
Mei GUAN
1
;
Zhao SUN
1
;
Chun Mei BAI
1
Author Information
1. Department of Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Review
- Keywords:
biomarker;
cancer;
immune checkpoint inhibitors;
immune-related adverse events
- MeSH:
Biomarkers;
Humans;
Immune Checkpoint Inhibitors/adverse effects*;
Immunotherapy/adverse effects*;
Neoplasms/drug therapy*
- From:
Acta Academiae Medicinae Sinicae
2020;42(6):825-830
- CountryChina
- Language:Chinese
-
Abstract:
While immune checkpoint inhibitors(ICIs)are effective and promising treatments for a variety of malignancies,they also have safety concerns,especially the immune-related adverse events(irAEs).Unlike the side effects of traditional chemotherapy and targeted therapy,irAEs are adverse events caused by immune activation after ICIs treatment and thus may involve almost every system of the body.Therefore,biomarkers for predicting irAEs after ICIs treatment are urgently needed.Here we review the currently available predictive biomarkers of irAEs.
